A large population based screening study published in JAMA examined more than 220,000 children in Germany to detect early, presymptomatic type 1 diabetes using islet autoantibody testing. The study aimed to understand how common early-stage disease is and how it progresses over time in the general pediatric population.
Researchers found that approximately 0.3% of children had early-stage (stage 1 or stage 2) type 1 diabetes, even though they showed no clinical symptoms at the time of screening. These cases were identified through routine testing in primary care settings, demonstrating that large-scale screening is feasible in real-world healthcare systems.
Over a median follow-up of about 5.7 years, around 36% of children with early-stage disease progressed to clinical type 1 diabetes, with an annual progression rate of roughly 9.6%. Notably, most children who eventually developed clinical diabetes had already been identified during the early screening phase, showing strong predictive value of the test.
The study concludes that population-wide screening can successfully identify children at risk before symptoms begin and may enable earlier monitoring and intervention strategies. It also supports the idea that screening should not be limited only to high-risk groups, as progression risk was similar regardless of family history.
Link: https://jamanetwork.com/journals/jama/fullarticle/2849402
